Every material Form 8-K MYRIAD GENETICS INC has filed with the SEC since October 20, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Myriad Genetics said it detected unauthorized access to its IT network on November 2, 2026, and temporarily suspended testing operations and order management systems while it investigates. The company said most systems have returned to normal, that it is still assessing whether any patient records were accessed, and that it does not believe the incident will have a material adverse effect on its business.
Unauthorized access detected on November 2, 2026, within the company's IT network environment
Testing operations and order management systems were temporarily suspended; most systems have since returned to normal operations
Whether patient records were accessed is still under investigation; external experts have been engaged
Company states it does not believe the incident will have a material adverse effect on its business
Myriad Genetics reported third-quarter 2026 revenue of $202.7 million, down 1% from a year earlier, with a net loss of $43.9 million, or $0.46 per share. The company raised the midpoint of its full-year 2026 revenue guidance to $780 million to $790 million and agreed on October 19, 2026 to sell its Prenatal Health business to Labcorp for $210 million in cash plus inventory.
Q3 2026 revenue $202.7 million, down from $205.7 million; Cancer Care Continuum and Mental Health volume up 3%, Prenatal Health volume down 11%
Q3 2026 operating loss $39.9 million; net loss $43.9 million, or $0.46 per share, versus $27.4 million a year earlier
Full-year 2026 revenue guidance $780 million to $790 million; Prenatal Health sale to Labcorp for $210 million in cash expected to close by early 2027
Myriad Genetics agreed on October 19, 2026 to sell its prenatal health testing business to Laboratory Corporation of America (Labcorp) for $210 million in cash, plus the value of the business's inventory at closing. The company says the sale is expected to be accretive to revenue growth and profitability and to strengthen its balance sheet, but the filing does not give Myriad's own revenue or profit figures for the business.
Price is $210 million in cash plus inventory value at closing, under an Asset Purchase Agreement dated October 19, 2026.
Labcorp expects the business to add approximately $160 million in revenue in year one and to be slightly accretive to its adjusted earnings in year one.
Closing is subject to regulatory clearance and customary conditions and is expected by early 2027; Buyer may owe Myriad a $10,500,000 termination fee if regulatory clearances fail.
Myriad plans to provide further commentary on the transaction and related organizational changes on its third quarter earnings call on November 4, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every MYRIAD GENETICS INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →